[1] Z. Tong et al., “Pancreas-specific Pten deficiency causes partial resistance to diabetes and elevated hepatic AKT signaling.,” Cell Res., vol. 19, no. 6, pp. 710–9, Jun. 2009.
[2] N. Wijesekara et al., “Muscle-specific Pten deletion protects against insulin resistance and diabetes.,” Mol. Cell. Biol., vol. 25, no. 3, pp. 1135–45, Feb. 2005.
[3] M. Delibegovic et al., “Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B.,” Mol. Cell. Biol., vol. 27, no. 21, pp. 7727–34, Nov. 2007.
[4] H.-C. Chuang and T.-H. Tan, “MAP4K4 and IL-6+ Th17 cells play important roles in non-obese type 2 diabetes.,” J. Biomed. Sci., vol. 24, no. 1, p. 4, Jan. 2017.
[5] R. Fragoso and J. T. Barata, “PTEN and leukemia stem cells.,” Adv. Biol. Regul., vol. 56, pp. 22–9, Sep. 2014.
[6] J. L. Rains and S. K. Jain, “Oxidative stress, insulin signaling, and diabetes.,” Free Radic. Biol. Med., vol. 50, no. 5, pp. 567–75, Mar. 2011.
[7] P. Manna and S. K. Jain, “Hydrogen sulfide and L-cysteine increase phosphatidylinositol 3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase (A,” J. Biol. Chem., vol. 286, no. 46, pp. 39848–59, Nov. 2011.
[8] D. H. Wasserman and J. E. Ayala, “Interaction of physiological mechanisms in control of muscle glucose uptake.,” Clin. Exp. Pharmacol. Physiol., vol. 32, no. 4, pp. 319–23, Apr. 2005.
[9] S. Alsadat, H. Khorami, A. Movahedi, K. Kuzwah, A. Mutalib, and M. Sokhini, “PI3K / AKT pathway in modulating glucose homeostasis and its alteration in Diabetes,” Ann. Med. Biomed. Sci., vol. 1, no. 2, pp. 46–55, 2015.
[10] N. R. Leslie, M. J. Dixon, M. Schenning, A. Gray, and I. H. Batty, “Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.,” Adv. Biol. Regul., vol. 52, no. 1, pp. 205–13, Jan. 2012.
[11] R. M. O’Brien, R. S. Streeper, J. E. Ayala, B. T. Stadelmaier, and L. A. Hornbuckle, “Insulin-regulated gene expression.,” Biochem. Soc. Trans., vol. 29, no. Pt 4, pp. 552–8, Aug. 2001.
[12] C. S. Choi, Y.-B. Kim, F. N. Lee, J. M. Zabolotny, B. B. Kahn, and J. H. Youn, “Lactate induces insulin resistance in skeletal muscle by suppressing glycolysis and impairing insulin signaling.,” Am. J. Physiol. Endocrinol. Metab., vol. 283, no. 2, pp. E233-40, Aug. 2002.
[13] G. Frangioudakis, J.-M. Ye, and G. J. Cooney, “Both saturated and n-6 polyunsaturated fat diets reduce phosphorylation of insulin receptor substrate-1 and protein kinase B in muscle during the initial stages of in vivo insulin stimulation.,” Endocrinology, vol. 146, no. 12, pp. 5596–603, Dec. 2005.
[14] L. P. Singh, D. Gennerette, S. Simmons, and E. D. Crook, “Glucose-induced insulin resistance of phosphatidylinositol 3’-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway.,” J. Diabetes Complications, vol. 15, no. 2, pp. 88–96, Jan. .
[15] P. Carlsson and M. Mahlapuu, “Forkhead transcription factors: key players in development and metabolism.,” Dev. Biol., vol. 250, no. 1, pp. 1–23, Oct. 2002.
[16] D. Chen et al., “p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity.,” Mol. Cell. Biol., vol. 24, no. 1, pp. 320–9, Jan. 2004.
[17] N. R. Leslie and C. P. Downes, “PTEN: The down side of PI 3-kinase signalling.,” Cell. Signal., vol. 14, no. 4, pp. 285–95, Apr. 2002.
[18] H. Ono et al., “Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.,” Mol. Endocrinol., vol. 15, no. 8, pp. 1411–22, Aug. 2001.
[19] B. Vanhaesebroeck and D. R. Alessi, “The PI3K-PDK1 connection: more than just a road to PKB.,” Biochem. J., vol. 346 Pt 3, pp. 561–76, Mar. 2000.
[20] T. McLaughlin, G. Allison, F. Abbasi, C. Lamendola, and G. Reaven, “Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals,” Metabolism, vol. 53, no. 4, pp. 495–499, Apr. 2004.
[21] R. MacLaren, W. Cui, S. Simard, and K. Cianflone, “Influence of obesity and insulin sensitivity on insulin signaling genes in human omental and subcutaneous adipose tissue.,” J. Lipid Res., vol. 49, no. 2, pp. 308–23, Feb. 2008.
[22] N. Rajkovic et al., “Relationship between Obesity, Adipocytokines and Inflammatory Markers in Type 2 Diabetes: Relevance for Cardiovascular Risk Prevention,” Int. J. Environ. Res. Public Health, vol. 11, no. 4, pp. 4049–4065, Apr. 2014.
[23] J. M. Lizcano and D. R. Alessi, “The insulin signalling pathway.,” Curr. Biol., vol. 12, no. 7, pp. R236-8, Apr. 2002.
[24] M. Hatting, C. D. J. Tavares, K. Sharabi, A. K. Rines, and P. Puigserver, “Insulin regulation of gluconeogenesis.,” Ann. N. Y. Acad. Sci., vol. 1411, no. 1, pp. 21–35, 2018.
[25] X. Liu, “Overstimulation can create health problems due to increases in PI3K/Akt/GSK3 insensitivity and GSK3 activity,” Springerplus, vol. 3, no. 1, p. 356, Dec. 2014.
[26] A. M. George, A. G. Jacob, and L. Fogelfeld, “Lean diabetes mellitus: An emerging entity in the era of obesity.,” World J. Diabetes, vol. 6, no. 4, pp. 613–20, May 2015.
[27] J. R. B. Perry et al., “Stratifying Type 2 Diabetes Cases by BMI Identifies Genetic Risk Variants in LAMA1 and Enrichment for Risk Variants in Lean Compared to Obese Cases,” PLoS Genet., vol. 8, no. 5, p. e1002741, May 2012.
[28] P. Gual, Y. Le Marchand-Brustel, and J. Tanti, “Positive and negative regulation of glucose uptake by hyperosmotic stress.,” Diabetes Metab., vol. 29, no. 6, pp. 566–75, Dec. 2003.
[29] K. Morino, K. F. Petersen, and G. I. Shulman, “Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.,” Diabetes, vol. 55 Suppl 2, pp. S9–S15, Dec. 2006.
[30] N. Nakashima, P. M. Sharma, T. Imamura, R. Bookstein, and J. M. Olefsky, “The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes.,” J. Biol. Chem., vol. 275, no. 17, pp. 12889–95, Apr. 2000.
[31] J. Zhou et al., “Inhibition of PTEN Activity Aggravates Post Renal Fibrosis in Mice with Ischemia Reperfusion-Induced Acute Kidney Injury.,” Cell. Physiol. Biochem., vol. 43, no. 5, pp. 1841–1854, 2017.
[32] J. Yang and Q. Chen, “The Effects of Acetylation of PTEN on Hepatic Gluconeogenesis,” J. Alzheimer’s Dis. Park., vol. 6, no. 3, pp. 1–7, Jun. 2016.
[33] J. Zhou et al., “Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury,” Oncotarget, vol. 8, no. 61, pp. 103154–103166, Nov. 2017.
[34] D. Ryu et al., “Endoplasmic Reticulum Stress Promotes LIPIN2-Dependent Hepatic Insulin Resistance,” Diabetes, vol. 60, no. 4, pp. 1072–1081, Apr. 2011.
[35] R. Neto-Ferreira, V. N. Rocha, V. Souza-Mello, C. A. Mandarim-de-Lacerda, and J. J. de Carvalho, “Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice,” Diabetol. Metab. Syndr., vol. 5, no. 1, p. 32, Jul. 2013.
[36] Y. Ye et al., “Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes,” Am. J. Physiol. Circ. Physiol., vol. 304, no. 1, pp. H131–H141, Jan. 2013.
[37] H. Gehart, S. Kumpf, A. Ittner, and R. Ricci, “MAPK signalling in cellular metabolism: stress or wellness?,” EMBO Rep., vol. 11, no. 11, pp. 834–40, Nov. 2010.
[38] A. Lawan et al., “Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.,” Mol. Cell. Biol., vol. 35, no. 1, pp. 26–40, Jan. 2015.
[39] D. Schmoll et al., “Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity.,” J. Biol. Chem., vol. 275, no. 46, pp. 36324–33, Nov. 2000.
[40] M. Lu et al., “Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1,” Nat. Med., vol. 18, no. 3, pp. 388–395, Mar. 2012.
[41] H. Cho et al., “Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).,” Science, vol. 292, no. 5522, pp. 1728–31, Jun. 2001.
[42] Q. F. Collins, Y. Xiong, E. G. Lupo, H.-Y. Liu, and W. Cao, “p38 Mitogen-activated Protein Kinase Mediates Free Fatty Acid-induced Gluconeogenesis in Hepatocytes,” J. Biol. Chem., vol. 281, no. 34, pp. 24336–24344, Aug. 2006.
[43] D. Miao, X.-K. Tong, G. K. Chan, D. Panda, P. S. McPherson, and D. Goltzman, “Parathyroid Hormone-related Peptide Stimulates Osteogenic Cell Proliferation through Protein Kinase C Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway,” J. Biol. Chem., vol. 276, no. 34, pp. 32204–32213, Aug. 2001.
[44] D. Santoleri and P. M. Titchenell, “Resolving the Paradox of Hepatic Insulin Resistance,” Cell. Mol. Gastroenterol. Hepatol., vol. 7, no. 2, pp. 447–456, Jan. 2019.
[45] V. T. Samuel et al., “Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.,” J. Biol. Chem., vol. 279, no. 31, pp. 32345–53, Jul. 2004.
[46] V. T. Samuel et al., “Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.,” J. Clin. Invest., vol. 117, no. 3, pp. 739–45, Mar. 2007.
[47] V. T. Samuel and G. I. Shulman, “The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux,” J. Clin. Invest., vol. 126, no. 1, pp. 12–22, Jan. 2016.
[48] L. Valenti et al., “Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis,” Diabetes, vol. 57, no. 5, pp. 1355–1362, May 2008.
[49] D. B. Pawlak, J. A. Kushner, and D. S. Ludwig, “Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals,” Lancet, vol. 364, no. 9436, pp. 778–785, Aug. 2004.
[50] W. Willett, J. Manson, and S. Liu, “Glycemic index, glycemic load, and risk of type 2 diabetes,” Am. J. Clin. Nutr., vol. 76, no. 1, pp. 274S-280S, Jul. 2002.
[51] R. S. Surwit et al., “Stress Management Improves Long-Term Glycemic Control in Type 2 Diabetes,” Diabetes Care, vol. 25, no. 1, pp. 30–34, Jan. 2002.
[52] J. I. Mechanick, “Metabolic Mechanisms of Stress Hyperglycemia,” J. Parenter. Enter. Nutr., vol. 30, no. 2, pp. 157–163, Mar. 2006.
[53] E. Barth et al., “Glucose metabolism and catecholamines.,” Crit. Care Med., vol. 35, no. 9 Suppl, pp. S508-18, Sep. 2007.
[54] K. Nonogaki, “New insights into sympathetic regulation of glucose and fat metabolism,” Diabetologia, vol. 43, no. 5, pp. 533–549, May 2000.
[55] N. Eigler, L. Saccà, and R. S. Sherwin, “Synergistic Interactions of Physiologic Increments of Glucagon, Epinephrine, and Cortisol in the Dog,” J. Clin. Invest., vol. 63, no. 1, pp. 114–123, Jan. 1979.
[56] J.-S. Chang et al., “Pattern of Stress-Induced Hyperglycemia according to Type of Diabetes: A Predator Stress Model.,” Diabetes Metab. J., vol. 37, no. 6, pp. 475–83, Dec. 2013.